Abeona Therapeutics Inc. · NASDAQ:ABEO
Abeona Therapeutics — Q1 2026 Earnings Presentation
19 slides from Abeona Therapeutics's earnings presentation, May 13, 2026
Slide 1: Investor Presentation
aN INVESTOR PRESENTATION
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempt
Slide 3: Corporate Overview
Corporate Overview Vishwas Seshadri, Ph.D., M.B.A. CHIEF EXECUTIVE OFFICER, DIRECTOR
Slide 4: ZEVASKYN Adoption Sets Foundation for Abeona's Growth
ZEVASKYN® Adoption Sets Foundation for Abeona’s Growth * Six Qualified Treatment Centers activated Net Rfoduct Revenue $87 cS —4 zevaskyn’ . Three patients treated in the first quarter (pratenagene zie) * Continued growth anticipated fueled by QTC expansion and positive early ZEVASKYN experiences *
Slide 5: Commercial Update
Commercial Update Madhav Vasanthavada, Ph.D., M.B.A. CHIEF COMMERCIAL OFFICER @ Abeona
Slide 6: Launch Momentum for ZEVASKYN Continues to Build
Launch Momentum for ZEVASKYN® Continues to Build ZEVASKYN Commercial Progress a s € g S a 6 * 942025 *As of May 13, 2026 Biopsy Scheduling In-progress Scheduled Treated Biopsied Treated 2026 2.2026" Patients Treated: +» 3 patients treated in the first quarter of 2026 » 1 patient treated so far this
Slide 7: Launch Insights and Data Updates Reinforce Conviction Across Stakeholders
Launch Insights and Data Updates Reinforce Conviction Across Stakeholders Patients treated span a wide age range, payor types, and have traveled significant distances, including out-of-state Published coverage policies now in place for 95% of commercially insured U.S. lives; no patient attrition and
Slide 8: Expanded QTC Network Enhances Patient Access
Expanded QTC Network Enhances Patient Access aT, \ 7 \ | ©)ann & Robert H. Lurie <—)\ 1 NewYork- a | Children’s Hospital of Chicago / ) = Presbyterian Q Stanford / ] Columbia University NW Children’s Health —~ YX Children's Hospital c Colorado 21 9 Reng pea eanee tes ra ~~ | Children's Hospital \—_,
Slide 9: R&D Pipeline Update
R&D Pipeline Update Vishwas Seshadri, Ph.D., M.B.A. CHIEF EXECUTIVE OFFICER, DIRECTOR
Slide 10: The ZEVASKYN Story Exemplifies Our Core Competencies
The ZEVASKYN® Story Exemplifies Our Core Competencies 14 ani ¢ \ ~ Tech ind Ri Ex, Tech transfer for manufacturing vectors and cell products Clinical development for personalized autologous cell-therapy Assay development, bridging and validation at every stage BLA review and approval with heavy CMC
Slide 11: Extending Our Competencies to Combat Advanced Prostate Cancer
Extending Our Competencies to Combat Advanced Prostate Cancer * PSMA is a validated target in prostate cancer, but CAR-Ts and other immunotherapies targeting PSMA have failed to deliver durable efficacy and acceptable safety profiles * PSMA SIR-T™ isa radically novel engineered T-cell technology wit
Slide 12: Cell Therapist
Cell Therapist Preet M. Chaudhary M.D., Ph.D. Professor of Medicine and Chief of Jane Ann Nohl Division of Hematology and Center for the Study of Blood Diseases at University of Southern California (USC) Keck School of Medicine Director of USC Blood and Marrow Transplant and Cell Therapy Program Ron
Slide 13: Synthetic Immune Receptor Combines the Best of CAR and TCR
Synthetic Immune Receptor Combines the Best of CAR and TCR PSMA SIR-T™ * Designed to overcome the fundamental limitations of CARs * Retains the full signaling strength, complexity, and physiological regulation of aTCR (ABO-701) * Exceptional in vivo responses vs. CAR T cells in preclinical models, w
Slide 14: PSMA SIR-T Demonstrated Better Tumor Remission and Durability
PSMA SIR-T™Demonstrated Better Tumor Remission and Durability Compared to CAR Controls with the Same PSMA Binding Domain Sassen] recente ssane a ava Ae a aa ree PSMA-SIR Percent survival Days after T cell injection ControlT [scfv-CAR__sVH-CAR, CAR
Slide 15: Financial Update
Financial Update Joe Vazzano CHIEF FINANCIAL OFFICER
Slide 16: Q1 2026 Financial Overview
Q1 2026 Financial Overview Q1 26 net product revenue of $8.7M vs. Q4 25 net product revenue of $2.4M Q1 26 cost of sales of $2.7M vs. Q4 25 cost of sales of $1.0M R&D expenses of $9.6M for Q1 26 (including $7.0M license payment for PSMA SIR-T™ asset) vs. §9.9M for Q1 25 SG&A expenses of $19.5M for Q
Slide 17: Conclusions
Conclusions Vishwas Seshadri, Ph.D., M.B.A. CHIEF EXECUTIVE OFFICER, DIRECTOR
Slide 18: Advancing Toward Our Mission With Every Step
Advancing Toward Our Mission With Every Step Strong Leading Indicators Advancing PSMA SIR-T™™ for ZEVASKYN’ Launch in Prostate Cancer Our mission to harness the promise of genetic medicine to transform the lives of patients is inspired by our vision, to realize a world where cure is the new standard
Slide 19: Questions
Questions